Personalized Medicine's Coming of Age: One Drug, One Patient.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

A dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.

Keyphrases

multiple myeloma
dendritic cells
case report
regulatory t cells
peripheral blood
newly diagnosed
immune response
stem cell transplantation
low dose
adverse drug
high dose